💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

AbbVie teams up with Morphic Therapeutic in fibrotic diseases

Published 10/18/2018, 08:23 AM
© Reuters.  AbbVie teams up with Morphic Therapeutic in fibrotic diseases
ABBV
-
  • AbbVie (NYSE:ABBV) inks an R&D collaboration agreement with Morphic Therapeutic aimed at advancing the latter's oral integrin therapies for fibrosis-related disorders.
  • Under the terms of the partnership, ABBV will pay Morphic $100M upfront for exclusive license options on selected candidates, milestones and tiered royalties on net sales. Morphic will conduct R&D through IND-enabling studies at which point ABBV may elect to pay a license fee to assume clinical development and commercialization. Morphic will retain cost-sharing rights for liver fibrosis indications and may elect to pay a portion of ABBV's development costs in exchange for higher royalties.
  • The companies are no strangers. AbbVie Ventures was an investor in its Series A and Series B financings.
  • Now read: Building A Dividend Growth Portfolio From Scratch: 15 'A' Rated Or Better Fairly Valued Opportunities


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.